関連する実験動画
Updated: Jul 17, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
アルツハイマー病の新型前駆体であるアミロイドタンパク質は,プロテアゼ抑制活性を示す
N Kitaguchi1, Y Takahashi, Y Tokushima
1Life Science Research Laboratories, Asahi Chemical Industry Co. Ltd., Shizuoka, Japan.
Nature
|February 11, 1988
まとめ
研究者らは,プロテアゼ阻害活性を持つ新しい形態のアミロイド前駆タンパク質 (APP) を特定しました. この発見は,アルツハイマー病における異常なAPP処理に光を当てるかもしれない.
科学分野:
- 神経科学は神経科学である.
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- アルツハイマー病は,脳内のアミロイドβタンパク質 (Aβ) の蓄積を伴う.
- アミロイド前駆体タンパク質 (APP) をコードする補完DNA (cDNA) は,以前,人間の脳組織からクローンされた.
研究 の 目的:
- APPの新しい形態とその潜在的な機能を調査する.
- APP遺伝子発現における代替スプライシングの影響を調査する.
主な方法:
- ヒトのグリオブラストーマ細胞系からcDNAを分離した.
- 孤立したcDNAとゲノムDNAの配列決定.
- COS-1細胞をAPPのcDNAで感染させ,トリプシン抑制の評価.
- 人間の脳のメッセンジャーRNA (mRNA) 種の分析.
主要な成果:
- 以前報告されたAPPのcDNAと異なる225ヌクレオチド挿入を含む新しいcDNAが特定されました.
- 挿入物の推論されたアミノ酸配列は,基本的なトリプシン阻害剤ファミリーとの同質性を示した.
- より長いAPPcDNAを発現するトランスフェクト細胞は,トリプシン抑制の強化を示した.
- APP遺伝子の代替スプライシングは,人間の脳で少なくとも3つの異なるmRNA種を生成します.
結論:
- 長いAPP変種は,プロテアゼ抑制活性を持っている.
- このプロテアゼ阻害は,異常なAPP分解と関連し,潜在的にアルツハイマー病の病理学に貢献している可能性があります.
関連する概念動画
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

